高级检索
当前位置: 首页 > 详情页

Cardioprotective Efficiency of Tangeretin Against Heart Failure Induced by Isoproterenol in Rats

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Wuhan Univ, Wuhan Hosp 3, Tongren Hosp, Dept Crit Care Med & Emergency, Wuhan 430074, Hubei, Peoples R China
出处:
ISSN:

关键词: Tangeretin myocardial infarction antioxidant apoptosis inflammation heart failure

摘要:
Background and Objective: Heart failure or myocardial infarction (MI) is one of the deadliest condition which claims many lives globally. This pre-clinical animal study was intended to investigate the beneficial role of Tangeretin (TAN) against isoproterenol (ISO) induced heart failure in a rat model. Materials and Methods: Forty healthy male rats were randomly separated into four group with 10 rats in each. Saline treat rats are considered as a control group, whereas ISO (85 mg kg(-1), i.p) induced rats (2 consecutive days) are considered as ISO group.The TAN (100 mg kg(-1) via o.p) pretreated rats for 28 days followed by induction of ISO will be considered as SAB-B+ISO group, only TAN (100 mg kg(-1), o.p) received rats for 28 days are considered as TAN group. Results: A pronounced increase in the levels of various hemodynamic parameters and the activities of antioxidants were observed in TAN pre-treated rats as compared to ISO-induced rats. However, the levels of infarct size, lipid peroxidation product like MDA, inflammatory markers, apoptotic markers are significantly decreased upon treatment with TAN for 28 days. Furthermore, TAN administration markedly reverted the histomorphological changes (cardiac tissue) caused by ISO induction. Conclusion: Taking together, that 28 days of pre-treatment with TAN significantly preserved cardiac function by suppressing oxidative stress, inflammation, apoptosis in ISO-induced heart failure (myocardial infarction) model and hence it can be recommended to treat myocardial infarction/heart failure with conventional (standard) cardio protective agents.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 药学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 药学
JCR分区:
出版当年[2016]版:
Q4 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Wuhan Univ, Wuhan Hosp 3, Tongren Hosp, Dept Crit Care Med & Emergency, Wuhan 430074, Hubei, Peoples R China
通讯作者:
通讯机构: [1]Wuhan Univ, Wuhan Hosp 3, Tongren Hosp, Dept Crit Care Med & Emergency, Wuhan 430074, Hubei, Peoples R China [*1]Department of Critical Care Medicine and Emergency, Tongren Hospital of Wuhan University, Wuhan Third Hospital, Wuhan, 430074, Hubei, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)